Results 221 to 230 of about 77,126 (264)

Aerosol and Oral Corticosteroids in the Treatment of Asthma

1988
The cause of asthma is unknown. However, it is now thought that the major abnormality is an underlying inflammation of the airway wall which persists, to some extent, between attacks. This inflammation manifests itself as bronchial hyperresponsiveness (BHR) which can be measured by inhalation tests from which dose response curves are derived.
A J, Woolcock, C, Jenkins
openaire   +2 more sources

Bronchial inflammation in corticosteroid‐sensitive and corticosteroid‐resistant asthma at baseline and on oral corticosteroid treatment

Clinical & Experimental Allergy, 2002
SummaryBackground Pathophysiology of corticosteroid (CS)‐resistant asthma remains incompletely understood.Objective To determine if failure of asthma to clinically improve with CS is due to a defective response of airway bronchial inflammation to these drugs.Methods Twenty‐one asthmatics having a decreased baseline FEV1 that improved ≥ 30% with inhaled
J, Chakir, Q, Hamid, M, Bossé, L-P, Boulet, M, Laviolette   +4 more
openaire   +2 more sources

Complications of Oral Corticosteroid Use in Otolaryngology

Annals of Otology, Rhinology & Laryngology
Objective: Oral corticosteroids (OCS) are frequently prescribed by otolaryngologists. However, there are limited quantitative data on OCS-related adverse events (AEs) in otolaryngology. We sought to quantify OCS-related AEs in otolaryngology. Methods: All outpatient otolaryngology encounters in our healthcare system (2018-2023) at which an OCS was ...
Margaret B. Mitchell, Alan D. Workman, Neil Bhattacharyya   +2 more
openaire   +2 more sources

Oral corticosteroids in the treatment of ocular myasthenia gravis

Neurology, 1974
Eight patients with ocular myasthenia gravis unresponsive to anticholines-terase medications were treated with alternate-day prednisone. Seven of the eight showed significant and sustained improvement. The patients exhibited few side effects of steroid therapy, and none manifested neurologic deterioration after institution of the therapy.
K C, Fischer, R J, Schwartzman
openaire   +3 more sources

Doxycycline or Oral Corticosteroids for Nasal Polyps

The Journal of Allergy and Clinical Immunology: In Practice, 2013
The study by Van Zele et al reports positive results for a randomized, double-blind, placebo-controlled trial that used either 20 days of doxycycline (200 mg the first day, followed by 100 mg daily) or 20 days of a tapering schedule of methyl prednisolone (32 mg on days 1-5, 16 mg on days 6-10, and 8 mg on days 11-20) for the treatment of nasal polyps.
openaire   +2 more sources

Safety of oral corticosteroids.

European journal of respiratory diseases. Supplement, 1983
Oral corticosteroids may be life-saving for symptoms of acute asthma, and short courses are often useful to relieve even less serious acute exacerbations when the patient has become inadequately responsive to bronchodilators. Adverse effects are rarely if ever associated with short courses of steroids used for this purpose.
openaire   +1 more source

Oral Corticosteroids

2022
Chengshuo Wang, Yifan Meng, Luo Zhang
openaire   +1 more source

Glaucoma and oral corticosteroids.

Prescrire international, 2001
(1) A case-control survey of patients over 65 taking oral steroids has shown a small rise in the risk of elevated intraocular pressure and glaucoma. (2) It seems advisable to monitor intraocular pressure in such patients, especially if they have a family history or other risk factors.
openaire   +1 more source

Oral Corticosteroids

2020
Sanjeev Handa, Manju Daroach
openaire   +1 more source

Oral Corticosteroids

2014
Enji Nakhla, Shyam Gelot
openaire   +1 more source